alexa Drug-Eluting <em>vs.</em> Bare-Metal Stents: Is it a Matter of Vessel Size? | OMICS International| Abstract
ISSN: 2167-0870

Journal of Clinical Trials
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
  • Research Article   
  • J Clin Trials 2017,
  • DOI: 10.4172/2167-0870.1000335

Drug-Eluting vs. Bare-Metal Stents: Is it a Matter of Vessel Size?

Mohamed Mehdi Boussaada*, Majed Hassine, Mejdi Ben Messaoud, Marouane Mahjoub, Zohra Dridi and Fethi Betbout
Department of Cardiology A, Fattouma Bourguiba University Hospital, Tunisia
*Corresponding Author : Mohamed Mehdi Boussaada, Department of Cardiology A, University of Monastir, Fattouma Bourguiba University Hospital, Tunisia, Tel: 0021621025715, Email: [email protected]

Received Date: Oct 29, 2017 / Accepted Date: Nov 14, 2017 / Published Date: Nov 16, 2017


Background: Although drug-eluting stents (DES) for percutaneous coronary intervention have dramatically reduced the incidence of in-stent restenosis, their deployment for large-size coronary lesions is still controversial because of problems such as prolonged dual antiplatelet therapy, late in-stent thrombosis and costs.
This study sought to evaluate the safety and effectiveness of drug-eluting stents (DES) compared to baremetal stents (BMS) for patients with large coronary vessels ≥ 3.5 mm.
: This is a retrospective case-control comparative study conducted in the cardiology A department of the university hospital Fattouma Bourguiba in Monastir. A total of 77 consecutive patients (80 lesions) who underwent, between October 2003 and March 2014, successfully DES implantation were compared to 73 consecutive patients (84 lesions) who were treated with BMS in large coronary vessels ≥ 3.5 mm.
The average age in our population was 59.7 ± 11.3 years with a male majority without any significant difference between the two groups. The DES group contained significantly more patients with diabetes (67.5% vs. 38.1%; p<0.0001) and a history of coronary heart disease (40% vs. 16.7%; p=0.001). The BMS group had significantly more procedures in the aftermath of MI (18.8% vs. 40.5%; p=0.002) including more primary angioplasty (6.7% against 47.1%; p=0.006). About two-thirds of the study patients had multi-vessel disease with equal distribution in both groups. The average duration of dual antiplatelet therapy was significantly prolonged in the DES group: 13.01 ± 8.31 months vs. 7.59 ± 8.19 months; p<0.0001. A mean follow of 27.87 ± 14.82 months was obtained. At 12 months, DES led to a significant reduction in the combined rate of major cardiac events by about 70% (OR=0.32; 95% CI: 0.119 to 0.858; p=0.019) without allowing a significant reduction in the rates of in-stent restenosis, in-stent thrombosis, target vessel revascularization or non-combined major cardiac events. During longterm follow-up, the benefit of DES in terms of MACE was maintained by allowing a 60% reduction in the combined rate of major cardiac events (OR=0.406; 95% CI: 0.172 to 0.955; p=0.035). Multivariate analysis identified the BMS as an independent predictor of major cardiac events and death. However, the type of stent does not appear as a factor influencing the ISR and target lesion revascularization rates.
The results of our study demonstrate a clear clinical benefit of drug-eluting stents during angioplasty of large coronary arteries in reducing major cardiac events and death without having any effect on in-stent restenosis, in-stent thrombosis nor target lesion revascularization.

Keywords: Large coronary arteries; Drug-eluting stent; Bare-metal stent; MACE

Citation: Boussaada MM, Hassine M, Messaoud MB, Mahjoub M, Dridi Z, et al. (2017) Drug-Eluting vs. Bare-Metal Stents: Is it a Matter of Vessel Size? J Clin Trials 7: 335. Doi: 10.4172/2167-0870.1000335

Copyright: © 2017 Boussaada MM, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Select your language of interest to view the total content in your interested language

Post Your Comment Citation
Share This Article
Article Usage
  • Total views: 1781
  • [From(publication date): 0-2017 - Dec 09, 2019]
  • Breakdown by view type
  • HTML page views: 1682
  • PDF downloads: 99